Precigen Secures Up to $125 Million Non-Dilutive Financing for Commercialization of PAPZIMEOS

Precigen has secured up to $125 million non-dilutive financing from Pharmakon Advisors. The funding will support the commercialization of PAPZIMEOS, expansion into international markets, and pursuit of pediatric and other HPV-related indications. The first tranche of $100 million was funded at closing, while a second tranche of $25 million can be drawn through March 31, 2027, subject to certain conditions.